Checkpoint Therapeutics Inc [CKPT] stock prices are up 10.94% to $3.65 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CKPT shares have gain 3.69% over the last week, with a monthly amount drifted -9.65%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, B. Riley Securities started tracking the stock with Buy rating on June 09, 2021, and set its price target to $18. On January 20, 2021, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $16 on the stock. Lake Street started tracking the stock assigning a Buy rating. H.C. Wainwright initiated its recommendation with a Buy and recommended $11 as its price target on December 08, 2017.
The stock price of Checkpoint Therapeutics Inc [CKPT] has been fluctuating between $1.38 and $4.50 over the past year. Checkpoint Therapeutics Inc [NASDAQ: CKPT] shares were valued at $3.65 at the most recent close of the market.
Analyzing the CKPT fundamentals
The Checkpoint Therapeutics Inc [NASDAQ:CKPT] reported sales of 0.05M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -451.68% with Operating Profit Margin at -798.17%, Pretax Profit Margin comes in at -988.68%, and Net Profit Margin reading is -988.68%. To continue investigating profitability, this company’s Return on Assets is posted at -8.97, Equity is 3.6 and Total Capital is 2.98.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.43 points at the first support level, and at 3.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.77, and for the 2nd resistance point, it is at 3.88.
Ratios To Look Out For
It’s worth pointing out that Checkpoint Therapeutics Inc [NASDAQ:CKPT]’s Current Ratio is 0.29. As well, the Quick Ratio is 0.29, while the Cash Ratio is 0.26. Considering the valuation of this stock, the price to sales ratio is 3954.87.
Transactions by insiders
Recent insider trading involved Oliviero James F III, CEO, President and Director, that happened on Dec 18 ’24 when 0.6 million shares were sold. CEO, President and Director, Oliviero James F III completed a deal on Dec 19 ’24 to sell 0.22 million shares. Meanwhile, Chief Financial Officer GRAY WILLIAM GARRETT sold 0.27 million shares on Dec 18 ’24.
